Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Lindemans, Caroline A  [Clear All Filters]
2018
de Koning C, Langenhorst J, van Kesteren C, Lindemans CA, Huitema ADR, Nierkens S, Boelens JJan. Innate immune recovery predicts CD4+ T-cell reconstitution after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018.
2019
Ferrua F, Galimberti S, Courteille V, Slatter MAnne, Booth C, Moshous D, Neven B, Blanche S, Laberko A, Shcherbina A, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT/ESID-IEWP-SCETIDE-PIDTC Study. J Allergy Clin Immunol. 2019.
Szanto CL, Langenhorst J, de Koning C, Nierkens S, Bierings M, Huitema ADR, Lindemans CA, Boelens JJ. Predictors for Autoimmune Cytopenias after Allogeneic Hematopoietic Cell Transplantation in Children. Biol Blood Marrow Transplant. 2019.
2020
Dandoy CE, Kim S, Chen M, Ahn KWoo, Ardura MI, Brown V, Chhabra S, Díaz MÁngel, Dvorak C, Farhadfar N, et al. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Netw Open. 2020;3(1):e1918668.
Wolf NI, Breur M, Plug B, Beerepoot S, Westerveld ASR, van Rappard DF, de Vries SI, Kole MHP, Vanderver A, Van der Knaap MS, et al. Metachromatic leukodystrophy and transplantation: remyelination, no cross-correction. Ann Clin Transl Neurol. 2020.
2021
G Y Rotte L, Loeffen YGT, Bierings MB, Wolfs TFW, Lindemans CA. Allogenic hematopoietic stem cell transplantation is feasible in pediatric patients with an active or recently diagnosed invasive fungal infection. Transplant Cell Ther. 2021.
Beerepoot S, Heijst H, Roos B, Wamelink MMC, Boelens JJan, Lindemans CA, van Hasselt PM, Jacobs EH, Van der Knaap MS, Teunissen CE, et al. Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy. Brain. 2021.
A Nijstad L, Nierkens S, Lindemans CA, Boelens JJan, Bierings M, A Versluys B, van der Elst KCM, Huitema ADR. Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in pediatric patients. Br J Clin Pharmacol. 2021.
Chiesa R, Boelens JJan, Duncan CN, Kuehl J-S, Sevin C, Kapoor N, Prasad VK, Lindemans CA, Jones SA, Amartino HM, et al. Variables Affecting Outcomes After Allogeneic Hematopoietic Stem Cell Transplant for Cerebral Adrenoleukodystrophy. Blood Adv. 2021.
2022
Lin C, Sajeev G, Stiff PJ, Brunstein CG, Cutler C, Sanz G, Lindemans CA, Rezvani AR, Hanna R, Koh LPiu, et al. Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel Versus Umbilical Cord Blood. Transplant Cell Ther. 2022.
Albert MH, Sirait T, Eikema D-J, Bakunina K, Wehr C, Suarez F, Fox MLaura, Mahlaoui N, Gennery AR, Lankester AC, et al. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity, an EBMT IEWP study. Blood. 2022.
Albert MH, Slatter MA, Gennery AR, Güngör T, Bakunina K, Markovitch B, Hazelaar S, Sirait T, Courteille V, Aiuti A, et al. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT inborn errors working party analysis. Blood. 2022.
Admiraal R, Nierkens S, Bierings MB, Bredius RGM, van Vliet I, Jiang Y, Lopez-Yurda M, A Versluijs B, C Zwaan M, Lindemans CA, et al. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. Lancet Haematol. 2022;9(2):e111-e120.
2023
Müskens KF, Lindemans CA, Dandis R, Nierkens S, Belderbos ME. Definitions, incidence and outcome of poor graft function after hematopoietic cell transplantation: A systematic review and meta-analysis. Blood Rev. 2023:101076.
Lucas AGTroullio, Lindemans CA, Bhoopalan SVelan, Dandis R, Prockop SE, Naik S, Keerthi D, de Koning C, Sharma A, Nierkens S, et al. Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis. Cytotherapy. 2023.
Kok G, Ilcken EF, Houwen RHJ, Lindemans CA, Nieuwenhuis EES, Spierings E, Fuchs SA. The Effect of Genetic HLA Matching on Liver Transplantation Outcome: A Systematic Review and Meta-Analysis. Ann Surg Open. 2023;4(3):e334.
Lucas AGTroullio, Boelens JJan, Prockop SE, Curran KJ, Bresters D, Kollen W, Versluys B, Bierings MB, Archer A, Davis E, et al. Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients. Front Oncol. 2023;13:1221782.
Szabolcs P, Mazor RD, Yackoubov D, Levy S, Stiff P, Rezvani A, Hanna R, Wagner J, Keating A, Lindemans CA, et al. Immune Reconstitution Profiling Suggests Antiviral Protection After Transplantation with Omidubicel: a Phase 3 Substudy. Transplant Cell Ther. 2023.
Ohm M, van Straalen JW, de Joode-Smink G, van Montfrans J, Bartels M, van Wildenbeest JG, Lindemans CA, Wennink RAw, de Boer JH, Sanders EAm, et al. Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study. Pediatr Rheumatol Online J. 2023;21(1):73.
Lin C, Schwarzbach A, Sanz J, Montesinos P, Stiff P, Parikh S, Brunstein C, Cutler C, Lindemans CA, Hanna R, et al. Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials. Transplant Cell Ther. 2023.
Böhm S, Wustrau K, Schmid JPachlopnik, Prader S, Ahlman M, Yacobovich J, Beier R, Speckmann C, Behnisch W, Ifversen M, et al. Survival in primary hemophagocytic lymphohistiocytosis 2016-2021: etoposide is better than its reputation. Blood. 2023.
2024
Arnhold V, Chang WY, Jansen SA, Thangavelu G, Calafiore M, Vinci P, Fu Y-Y, Ito T, Takashima S, Egorova A, et al. Corticosteroids impair epithelial regeneration in immune-mediated intestinal damage. J Clin Invest. 2024.
Eskandari SK, Revenich EGM, Pot DJ, de Boer F, Bierings M, van Spronsen FJ, van Hasselt PM, Lindemans CA, Lubout CMA. High-Dose ERT, Rituximab, and Early HSCT in an Infant with Wolman's Disease. N Engl J Med. 2024;390(7):623-629.